Representatives from the Life Raft Group recently traveled to Prague, Czech Republic to attend the annual Connective Tissue Oncology Society (CTOS) meeting. CTOS is an international group comprised of physicians and scientists with a primary interest in the tumors of connective tissues.
Drs. Jonathan Fletcher, of Brigham & Women’s Hospital, Harvard University and Maria Debiec-Rychter, of the Catholic University in Leuven, Belgium, members of the LRG Research Team were part of a recently published study that looked at the effectiveness of GDC-0941, a PI3K inhibitor when used in combination with imatinib (Gleevec).
By Drs. Sebastian Bauer, West German Cancer Center, University of Essen, Germany and Jonathan Fletcher, Brigham & Women’s Hospital, Harvard University, LRG Research Team Researchers talk plainly about microGISTs, how this cancer develops and what all [...]
How does a $2 million-a-year cancer research effort with a team of nine scientists keep pace with a $100 million-a-year project with a team of 200? Pretty well, it turns out. With the Cancer Genome Atlas project in the news lately—the New York Times recently reported on progress in its colon cancer work—we decided to compare some of its data with that of the Life Raft Group’s Research Team and its D-Day Project. Our research focuses on GIST.
The main functions of the gastrointestinal tract are to secrete digestive juices, break down food components, absorb nutrients, reclaim water and excrete waste, which are performed by the mucosal lining of the gut...
